Investing.com - Atara Biotherapeutics Inc (NASDAQ: ATRA) reported first quarter EPS of $-0.2300, worse than the analyst estimate of $-0.2267. Revenue for the quarter came in at $27.36M versus the consensus estimate of $27.92M.
Atara Biotherapeutics Inc's stock price closed at $0.55. It is down -33.4400% in the last 3 months and down -77.5400% in the last 12 months.
Atara Biotherapeutics Inc saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Atara Biotherapeutics Inc's stock price’s past reactions to earnings here.
According to InvestingPro, Atara Biotherapeutics Inc's Financial Health score is "weak performance".
Check out Atara Biotherapeutics Inc's recent earnings performance, and Atara Biotherapeutics Inc's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar